Sofiva Genomics Co.,Ltd.
Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M… Read more
Sofiva Genomics Co.,Ltd. (6615) - Net Assets
Latest net assets as of : NT$- TWD
Based on the latest financial reports, Sofiva Genomics Co.,Ltd. (6615) has net assets worth NT$- TWD as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$-) and total liabilities (NT$-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Sofiva Genomics Co.,Ltd. - Net Assets Trend (None–None)
This chart illustrates how Sofiva Genomics Co.,Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sofiva Genomics Co.,Ltd. (None–None)
The table below shows the annual net assets of Sofiva Genomics Co.,Ltd. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to Sofiva Genomics Co.,Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Sofiva Genomics Co.,Ltd. Competitors by Market Cap
The table below lists competitors of Sofiva Genomics Co.,Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PLASTIC INDUSTRY (MAURITIUS) LTD
SEM:PIM
|
$9.40K |
|
102950
KO:102950
|
$9.40K |
|
PTT NVDR
MU:NVA3
|
$9.41K |
|
189350
KO:189350
|
$9.41K |
|
341170
KO:341170
|
$9.38K |
|
Science in Sport plc
LSE:SIS
|
$9.38K |
|
SAPIENT CORPORATION
BE:SPC
|
$9.37K |
|
Nations Trust Bank PLC
CM:NTBN0000
|
$9.37K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sofiva Genomics Co.,Ltd.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Sofiva Genomics Co.,Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Sofiva Genomics Co.,Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares Sofiva Genomics Co.,Ltd.'s net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $488,063,857
- Average return on equity (ROE) among peers: 1.33%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sofiva Genomics Co.,Ltd. (6615) | NT$- | N/A | N/A | $9.38K |
| Bionet (1784) | $1.32 Billion | 2.02% | 0.36x | $107.18 Million |
| DIVA Laboratories Ltd (4153) | $1.02 Billion | 4.89% | 0.23x | $25.67 Million |
| Kim Forest Enterprise Co., Ltd. (6645) | $32.49 Million | 0.00% | 7.10x | $20.40 Million |
| Welgene Biotech Co.Ltd. (6661) | $246.55 Million | 11.49% | 0.47x | $3.31 Million |
| Puriblood Medical Co., Ltd. (6847) | $175.40 Million | -3.06% | 0.48x | $13.28 Million |
| TFBS Bioscience Inc. (6939) | $247.95 Million | 0.12% | 0.16x | $5.40K |
| Pharmigene, Inc. (7595) | $382.22 Million | -6.13% | 0.10x | $10.10 Million |